DGAP-News: MeVis Medical Solutions AG / Key word(s): Preliminary Results/Forecast MeVis Medical Solutions AG: Preliminary figures 2013: MeVis forecast fully met / First guidance for 2014 05.03.2014 / 07:30 --------------------------------------------------------------------- 2013 strongest year since IPO in 2007 - Group revenues increased by 10 % year on year to EUR 14.6 m - Earnings before interest and taxes (EBIT) increased significantly by EUR 1.0 m to EUR 4,0 m - Liquidity increased by EUR 5.3 m to EUR 14.0 m (Dec.31, 2012: EUR 8.7 m) - Guidance for 2014 (starting 2014 MBC will be consolidated at-equity and not proportionally): - Revenues between EUR 12.0 m and EUR 12.5 m - EBIT between EUR 3.0 m and EUR 3.5 m - Liquidity between EUR 15 m and EUR 16 m by the end of 2014 Bremen, March 5, 2014 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its preliminary figures for fiscal year 2013. The group revenues generated in 2013 amounted to EUR 14.6 m, up 10 % compared to the previous year's revenues of EUR 13.3 m. The increase in licensing business by 11 % from EUR 6.9 m to EUR 7.7 m as well as an increase in non-recurring engineering contrbutions of EUR 0.5 m to EUR 1.0 m contributed to this growth. Maintenance revenues remained stable at EUR 5.9 m. The increase in revenues resulted almost entirely from the Digital Mammography segment, where revenues rose from EUR 10.1 m to EUR 11.3 m, while revenues in the Other Diagnostics segment rose only marginally from EUR 3.2 m to EUR 3.3 m. Operating costs could be reduced again in 2013 as staff costs decreased by EUR 0.2 m from EUR 8.1 m to EUR 7.9 m and other operating expenses by as much as EUR 0.4 m from EUR 2.3 m to EUR 1.9 m. In 2013 the capitalization of development costs has been cut nearly in half by EUR 1.0 m from EUR 2.4 m to EUR 1.4 m. This effect is almost entirely offset by a decrease in depreciation of EUR 0.9 m from EUR 3.0 m to EUR 2.1 m. For 2013 this results in an EBIT (earnings before interest and taxes) of EUR 4.0 m, which is EUR 1.0 m higher than previous year and corresponds to an EBIT margin of 27 % (previous year: 21 %). Cash and cash equivalents increased significantly in 2013 and amounted to EUR 14.0 m at year-end (compared to EUR 8.7 m as at December 31, 2012). In addition to the good operating performance the reduction of receivables has been instrumental to this very strong cash flow of EUR 5.3 m. "We are pleased with the very positive development in 2013. In 2014, in accordance with the new IFRS 11, we will no longer consolidate our joint venture with Siemens MeVis Breast Care proportionately but under the at-equity method, with corresponding effects on revenues, costs and liquidity among other things. Based on this, for 2014 we expect revenues between EUR 12.0 and EUR 12.5 m. This is a slight decrease compared to the extremely positive year 2013, for which, on a comparable basis, revenues of EUR 12.8 m would have been reported. We expect an EBIT of between EUR 3.0 and EUR 3.5 m, which is lower than the adjusted previous year's figure of EUR 4.4 m due to the slight decline in revenues and a selective increase of resources for development and sales. Liquidity should increase again in 2014 and at the end of 2014 we anticipate a liquidity between EUR 15.0 and EUR 16.0 m compared with a value of EUR 13.4 m at the end of 2013 on a comparable basis." said Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. "Following the announcement of our industrial customer Hologic in January of this year, that in the medium-term an altered form of cooperation with MeVis is sought, we are very pleased that, a few days ago, we were able to extend the current contract until the end of 2015 at the existing terms. Apart from that, MeVis will continue to strongly focus on the development and implementation of measures designed to generate future sales growth. We will utilize and expand our clinical and technological expertise in order to hold a prominent market position in our core fields breast, lung and liver imaging. Our goal for the financial year 2014 is to expand our industrial customers segment and to broaden the marketing of our MeVis Online Services." added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. The final consolidated financial statement and the group management report will be published on April 24, 2014. End of Corporate News --------------------------------------------------------------------- 05.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 255718 05.03.2014